Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our researchers have discovered an unexpected way by which different pathways of the skin’s defence system interact, and how they can go astray in skin inflammation. This suggests a new line of investigation to develop treatments for conditions such as eczema.

Dr Clare Hardman (lead author) and Prof Graham Ogg (senior author)

The skin’s immune system is our first line of defence against invading pathogens. In certain conditions this protective system can act in an uncontrolled way, leading to skin inflammatory conditions. Prof Graham Ogg of the MRC Human Immunology Unit (Radcliffe Department of Medicine) is studying an inflammatory skin disease called atopic eczema (or atopic dermatitis). “Atopic eczema affects 20-30% of children and 5-10% of adults in the UK. It is related to other allergic diseases such as asthma, hay fever and food allergies, which collectively carry an enormous burden on patients and their families”, says Prof Ogg. “If we can understand the pathways of disease in atopic eczema then we may be able to identify new routes to treatment”.

An important question in understanding how the skin immune system works, and how it goes astray, concerns whether the several players at work are able to interact. One such player is a population of Group 2 Innate Lymphoid Cells, also known as ILC2s. ILC2s act as sentinels, triggering other immune pathways when invading pathogens are detected. In their publication in Science Immunology, Prof Ogg and his team looked for clues on how ILC2s act, and how they interact with other pathways in inflammation. In order to do so, they examined healthy volunteers and patients with eczema, using a skin suction technique. Skin biopsies (where a piece of tissue is removed) are the conventional method used to study skin cells. This approach is not ideal, as examination of individual cells requires the tissue to be disrupted, which can interfere with the results. “In our approach, a suction cup is applied over the skin, which forms a blister similar to those you can develop in the back of your foot.” explained Prof Ogg “The fluid within these blisters contains cells that are already separated, so no further processing is required.”

Using this technique, the researchers showed that ILC2s are able to interact with CD1a-reactive T cells, another immune response pathway suspected to play a role in allergy and infection. The team showed that ILC2s signal information about the presence of allergens (such as house dust mite) or invading pathogens (such as Staphylococcus aureus) to the T-cells, but also trigger immune responses in unwanted contexts, such as in atopic eczema.

Importantly, these results suggest possible targets for future therapies. The team showed that the ILC2s can amplify subsequent immune responses by binding and presenting particular fat molecules, which can trigger an inflammation cascade “That cascade of inflammation can include the production of messenger molecules called cytokines. This offers the possibility of interfering with those cytokines for future treatment development.” explains Prof Ogg “Our next steps are to understand the nature of the fats that are triggering the immune cascade and the nature of the particular cytokines that the cells are producing, so that they might be modulated in future treatments.”


This work was supported by the NIHR Oxford Biomedical Research Centre, NIHR Comprehensive Research Network and the MRC.

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.